Brief: Guardant Health Receives FDA Approval For Guardant360® Cdx As A Companion Diagnostic For Arvinas And Pfizer’S Veppanu (Vepdegestrant) For Patients With Er+/Her2- Advanced Breast Cancer With Esr1 Mutations
04/05/2026 13:14
May 4 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH RECEIVES FDA APPROVAL FOR GUARDANT360® CDX AS A COMPANION DIAGNOSTIC FOR ARVINAS AND PFIZER’S VEPPANU (VEPDEGESTRANT) FOR PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER WITH ESR1 MUTATIONS Source text: ID:nBw8zNSt7a Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsU.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte